Nanosuspension - a new approach of bioavailability enhancement

International Journal of Pharmaceutical Sciences Review and Research

Volumn 8, Issue 2, 2011, Pages 61-65

  Wagh, Kalpesh S ^a   Patil, Satish K ^a   Akarte, Anup K ^a   Baviskar, Dheeraj T ^a  

^a Institute of Pharmaceutical Education   (India)

Author keywords

Nanosuspension; Saturation solubility; Solubility enhancement

Indexed keywords

NANOCRYSTAL; ORGANIC SOLVENT; STABILIZING AGENT; SURFACTANT;

CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; GRINDING; IN VITRO STUDY; IN VIVO STUDY; NANOANALYSIS; NANOBIOTECHNOLOGY; NANOEMULSION; NANOENGINEERING; NANOSUSPENSION; PARTICLE SIZE; PRECIPITATION; REVIEW; SUPERCRITICAL FLUID; SUSPENSION; ZETA POTENTIAL;

EID: 80052697846     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Dubey R, Pure drug nanosuspensions impact of nanosuspensions technology on discovery and development. Drug Del. Tech 6, 2006, 65-71.
2. Aboofazeli R, Barlow DJ, Lawrence MJ. Particle size analysis of concentrated phospholipids microemulsions: II. Photon correlation spectroscopy. AAPS Pharm. sci. 2, 2000, 1-10.
3. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomed, Nanotech. Biol. Med. 5, 2009, 90-95.
4. Rao GCS, Satish KM, Mathivnan N, Rao EB. Advances in nanoparticulate drug delivery systems. Ind. Drugs. 7, 2004, 389-95.
5. Akers MJ. Excipient-drug interactions in parenteral formulations. J. Pharm. Sci. 91, 2005, 2283-2300.
6. Allen TM. Liposomes, opportunities in drug delivery. Drugs 54, 1997, 8-14.
7. Muller RH, Bohm BHL, Grau J. Nanosuspensions: a formulation approach for poorly soluble and poorly bioavailable drugs. In D. Wise (Ed.) Handbook of pharmaceutical controlled release technology. 17, 2000, 345-57.
8. Chowdary KPR, Madhavi BLR. Novel drug delivery technologies for insoluble drugs. Ind. Drugs. 42(9), 2005, 557-563.
9. Cornelia MK, Rainer H, Muller. Drug nanocrystals of poorly soluble drugs produced high-pressure homogenizations. Eur. J. Pharm. Biopharm 62, 2006, 3-16.
10. Patravale B, Abhijit AD, and Kulkarni RM, Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharcol. 56, 2004, 827-40.
11. Kayser O. Nanosuspensions for the formulation of aphidicol into improve drug targeting effects against Leishmania infected macrophages. Int. J. Pharm. 196, 2000, 253-56.
12. Krause KP, Kayser O, Mader K, Gust R, Muller RH. Heavy metal intamination of nanosuspensions produced by highpressure homogenizations. Int J. Pharm. 196, 2000, 169-72
13. Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intraveneously injectable chemically stable aqueous omeprazole formulation using nanosuspensions. Eur. J. Pharm. Biopharm. 58, 2004, 615-19.
14. Nanopure RM. Pure drug nanoparticles for the formulation of poorly soluble drug. New Drug. 54, 2001, 62-8.
15. Barret ER. Nanosuspensions in drug delivery. Nat. rev. 3, 2004, 785-96.
16. Wongmekiat A, Tozuka Y, Oguchi T and Yamamoto K: Formation of fine drug particles by co-grinding with cyclodextrin. I. the use of â-cyclodextrin anhydrate and hydrate. Pharm Res, 19, 2002, 1867-72.
17. Okagaki MT, Narisawa S, Koida Y and Nakajima K: Improvement of dissolution characteristics and bioavailability of poorly water-soluble drugs by novel cogrinding method using water solublie polymer. Int J Pharm, 160, 1998, 11-9.
18. Wong JC, Doty MJ, Rebbeck CL. Microprecipitation method for preparing submicron suspensions. US Patent no. 6: 2003, 607-784.
19. Dearns R. Atovaquone pharmaceutical composition. US 601880, 2000.
20. Irene P, Ruggero B, Ferdinando G. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics, European journal of pharmaceutical sciences 27, 2006, 299-310.
21. Hamsaraj K, Shenoy VS, Murthy RR. Industrially Feasible Alternative Approaches in the Manufacture of Solid Dispersions: A Technical Report, AAPS Pharm SciTech 7(4), 2006, 87.
22. Kawakami K, Yoshikawa T. Microemulsion's formulation for enhanced absorption of poorly soluble drugs prescription design. J. Control. Release 81, 2000, 65-74.
23. Kayser O. Nanosuspensions for the formulation of aphidicolinto improve drug targeting effects against Leishmaniainfected macrophages. Int. J. Pharm. 196, 2000, 253-56
24. Kayser O. A new approach for targeting to Cryptosporidiumparvum using mucoadhesive nanosuspensions research and applications. Int. J. Pharm. 214, 2001, 83-85.
25. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future. Ad. Drug Del. Rev. 47, 2001, 3-19.
26. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after 1st delivery across the blood-brain barrier using surfactant coated nanoparticles. J Control Release. 49, 1997, 81-87.